About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
8th Eurasian Hematology Oncology Summit
Videos
Event
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
G
2021 Highlights on Higher Risk MDS: Can We Improve on Azacitidine? What Are the Options for High-Risk HMA Failure? How to Integrate alloSCT?
By
8th Eurasian Hematology Oncology Summit
FEATURING
Guillermo Garcia-Manero
By
8th Eurasian Hematology Oncology Summit
FEATURING
Guillermo Garcia-Manero
237 views
May 13, 2021
0 Comments
Login to view comments.
Click here to Login
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
Featured Video
13:04
Winship Cancer Institute - Emory University
Treatment-Related Quality of Life in MF
Feat.
A. Hunter
Videos
14:53
8th Eurasian Hematology Oncology Summit
Maintenance Therapy in AML: Overview of Outcomes and Future Approach…
Feat.
T. Kadia
13:09
8th Eurasian Hematology Oncology Summit
Brentuximab Vedotin in HL: Evaluating the Clinical Data
Feat.
C. Gisselbrecht
10:10
8th Eurasian Hematology Oncology Summit
The Role of MRD in AML: Navigating Testing Techniques & Predicti…
Feat.
T. Kadia
19:17
8th Eurasian Hematology Oncology Summit
Treating Myelofibrosis in 2021: What Are the Efficacy Data for Ruxol…
Feat.
H. Kathrin Al-Ali
19:08
8th Eurasian Hematology Oncology Summit
2021 Efficacy Data Review in Relapsed CLL: BTK Inhibitors, Ven+/-Rit…
Feat.
S. O'Brien
16:00
8th Eurasian Hematology Oncology Summit
Frontline Treatment of CLL: Surveying Outcomes With BTKi / BCL-2i Op…
Feat.
S. O'Brien
09:15
8th Eurasian Hematology Oncology Summit
How I Treat ET in 2021: WHO True-ET, Thromboembolic/Bleeding Complic…
Feat.
D. Wolf
10:04
8th Eurasian Hematology Oncology Summit
How I Treat PV in 2021: JAKi in Symptomatic Disease, Anti-Clonal Act…
Feat.
D. Wolf
14:23
8th Eurasian Hematology Oncology Summit
Surveying the Data on DLBCL Treatments: RT Therapy in the PET Era, I…
Feat.
U. Vitolo
05:47
8th Eurasian Hematology Oncology Summit
R/R DLBCL: Novel Strategies in 1L/2L Treatment
Feat.
U. Vitolo
06:03
8th Eurasian Hematology Oncology Summit
Novel Strategies in 1/2L Large Cell Lymphoma: Navigating Treatment O…
Feat.
U. Vitolo
07:18
8th Eurasian Hematology Oncology Summit
How Important Is Imaging (PET) for 1L Early Stage HL?
Feat.
C. Gisselbrecht
21:14
8th Eurasian Hematology Oncology Summit
2021 Treatment Considerations for Follicular Lymphoma: Localized, Ad…
Feat.
G. Gaidano
12:00
8th Eurasian Hematology Oncology Summit
Navigating Treatment Options for Newly Diagnosed ASCT-Eligible MM in…
Feat.
A. Maiolino
07:11
8th Eurasian Hematology Oncology Summit
Survival Data for Newly Diagnosed ASCT-Ineligible MM: VRd vs. Rd, VM…
Feat.
A. Maiolino
21:36
8th Eurasian Hematology Oncology Summit
CAR-T Cell Therapy for Multiple Myeloma
Feat.
E. Terpos
07:00
8th Eurasian Hematology Oncology Summit
MRD in CLL: What Were the Changes and Issues Over the Years? Is This…
Feat.
R. Foa
17:18
8th Eurasian Hematology Oncology Summit
2021 Updates on MRD in CLL: Chemoimmunotherapy vs. Targeted Approach…
Feat.
R. Foa
06:59
8th Eurasian Hematology Oncology Summit
2021 Oral HMAs Efficacy Data in MDS: Decitabine + Cedazuridine for H…
Feat.
G. Garcia-Manero
15:42
8th Eurasian Hematology Oncology Summit
2021 MDS Highlights: Luspatercept for Very Low-Intermediate Risk, Im…
Feat.
G. Garcia-Manero
20:55
8th Eurasian Hematology Oncology Summit
2021 Lower Risk MDS Updates: RBC Transfusions, ESA in Anemia, Lenali…
Feat.
M. Mittelman
13:39
8th Eurasian Hematology Oncology Summit
2021 Highlights on Higher Risk MDS: Can We Improve on Azacitidine? W…
Feat.
G. Garcia-Manero
25:12
8th Eurasian Hematology Oncology Summit
2021 Updates on TFR in CML: What Are the Factors and Best Predictors…
Feat.
G. Saglio
21:28
8th Eurasian Hematology Oncology Summit
How to Treat Newly Diagnosed AML in Unfit Patients: Pretreatment Tes…
Feat.
T. Kadia
08:17
8th Eurasian Hematology Oncology Summit
Highlights on ETP-ALL: Recognition, Role of Allogeneic Transplant, C…
Feat.
S. Chiaretti
13:48
8th Eurasian Hematology Oncology Summit
Updates on Ph-Like ALL: Genomic Background, Diagnosis, Outcomes, and…
Feat.
S. Chiaretti